Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK)
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.03.11.22272276: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: COVIDENCE UK is registered with ClinicalTrials.gov, NCT04330599, and was approved by Leicester South Research Ethics Committee (ref 20/EM/0117).
Consent: All participants provided informed consent to participate.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources To produce participant-level covariates for each class of medications investigated, questionnaire responses were mapped to drug classes listed in the British National Formulary or the DrugBank and Electronic Medicines Compendium databases if not explicitly listed in the British National Formulary, as … SciScore for 10.1101/2022.03.11.22272276: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: COVIDENCE UK is registered with ClinicalTrials.gov, NCT04330599, and was approved by Leicester South Research Ethics Committee (ref 20/EM/0117).
Consent: All participants provided informed consent to participate.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources To produce participant-level covariates for each class of medications investigated, questionnaire responses were mapped to drug classes listed in the British National Formulary or the DrugBank and Electronic Medicines Compendium databases if not explicitly listed in the British National Formulary, as previously described. DrugBanksuggested: (DrugBank, RRID:SCR_002700)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study also has some limitations. First, we were unable to identify the strain of the infections, meaning that we could not dissect differences between the delta and omicron variants that were both dominant at different points in our study; however, more than 90% of the breakthrough infections in our post-booster analysis occurred after omicron became dominant in the UK, suggesting it largely captures the effects of that variant. Second, with very few hospitalisations, we did not have the power to assess risk factors for different levels of disease severity in vaccinated individuals. Third, as a self-selected cohort, several groups—including people younger than 30 years, people of lower socioeconomic status, and non-White ethnic groups—are under-represented in COVIDENCE UK. Lack of representativeness is not necessarily a barrier to valid scientific inference, however.37 Fourth, as with any observational study, it is possible that some of the associations we report can be explained by residual or unmeasured confounding; we have attempted to minimise this by adjusting for a comprehensive range of potential risk factors for infection, made possible by the large number of breakthrough infections recorded in our study (ie, >30 events per variable in each fully adjusted model). Finally, we explored several potential associations and cannot exclude the possibility that some achieved statistical significance as a result of type 1 error; however, by including the same predictors i...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04330599 Active, not recruiting Longitudinal Population-based Observational Study of COVID-1… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
